Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
- Fiscal strength with significant cash, ongoing revenues and potential milestone payments
- Productive partnerships with top-tier pharmaceutical companies
- Rich product portfolio with multiple drugs in clinical development
- Visionary leadership backed by a world-class management team
We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.Financially Strong
We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver nearly $2 billion in product milestones plus royalties.
Dr Martin Buckland
Dr Stuart Hwang
Domainex is an integrated drug discovery services company, which uses its medicinal chemistry expertise, its in silico hit screening approach and proprietary discovery technology platform, CDH, to improve efficiency in developing drug candidates.
- LeadBuilder, is a state-of-the-art virtual screening capability that identifies compounds with "lead-like" properties, ideal for progressing to drug candidates and saving 6-12 months on standard approaches.
- Combinatorial Domain Hunting (CDH), enables the fast identification of expressible (in E.coli or baculovirus) domains of drug target protein, which are able to bind ligand.
The identified protein domains are then used to quickly develop binding/activity assays for use in small molecule hit screening. This entire process only takes 4-5 months for novel drug targets and so can quickly de-rate limit exciting and challenging discovery programs. The Domainex services enhance drug discovery projects from target expression to small molecule lead optimization. Its success is illustrated by the number of drug candidates it has developed with 6 projects reaching Candidate Drug in the last 4 years (3 currently in the clinic). This success has been due to Domainex's focus on high quality, intelligence-driven drug design, supported by the expertise of its scientists.
Dr Eddy Littler
Dr Joanne McCudden
Saccharides Science and Technology
Through the novel application of gap analysis methods in disease biotechnology, SST develops medications that serve as biochemical prostheses that bridge broken reaction pathways, create a normal physiological environment and programme the body to build a natural resistance to the disease. Unlike conventional treatments that act to directly suppress diseases rapidly often with adverse side- effects, SST’s products are designed to gradually correct genetic faults and biochemical mistakes that underlie these diseases.
SST has been developing a series of patented pharmaceutical and medical device technologies and has found commercial success in its product, Amzylite F1.2, the first of its many upcoming diabetic oral medications.
Dr Tarig ArbabExecutive Director
Theryte is a drug discovery and development company that is committed to bringing revolutionary new cancer treatments to market.
Theryte's new approach targets the processes that normally stabilise the cancer cell, allowing the creation of novel, first-in-class anti-cancer drugs with a unique mechanism of action and efficacy against difficult-to-treat tumours.
Theryte aims to exploit its patented discoveries to: (i) develop the breakthrough technology to select pre-clinical candidates for partnering and licensing; (ii) advance a new family of anticancer targets for further drug development; and (iii) develop biomarkers to predict treatment response.